Our technology is unique. It is designed to direct the patient’s own immune cells to mount a comprehensive and sustained attack directed specifically against their own cancer tissue.

WHY WE FIGHT BETTER?

Most advanced cancer immunotherapies struggle with solid tumors because they target only one or a few antigens, lose effectiveness as immune cells exhaust over time, and fail to overcome the tumor’s powerful evasion mechanisms. CAR-T, CAR-NK, and antibody-drug conjugates deliver limited, short-lived responses and often require patient pre-selection.

We train patient immune system against complexities: Solid tumors are composed of many cell types → complex antigen profile. Tidewave Bio addresses this complexity using the patient own tumor tissue to create a broad repertoire of cancer antigen tailored to each patient in realtime.

The result: When combined with our engineered antigen presenting cells, patients can mount a broad attack on cancer

Using specific gene modifications, our cell are engineered to secrete signaling molecules telling your immune cells to break through tumor protection mechanisms (immune evasion).

Tidewave Bio’s advance cell therapy not only induces potent cancer killing cells, they also establish durable protection that may prevent reccurences.

Cell report paper

REAL-time precision medicine at the bedside

Product stored on site off-the-shelf

On the day of a diagnostic biopsy, a simple disposable devices prepares a tumor antigen sample from a small portion of the cancer biopsy. This sample is then combined with our universal, gene-enhanced antigen-presenting cells. The process instantly transforms Tidewave Bio’s off the shelf universal product into a patient-specific precision therapy loaded with a broad spectrum of tumor antigens.

A simple intradermal injection, trains the patient’s immune system to mount a comprehensive, immune evasion busting, lasting attack against solid tumors.

More about the science? And where we stand? Download our corporate deck.

Download deck

Find answers about our mission

Are Tidewave Bio Therapy Candidate FDA approved or available Clinically?

No, Tidewave Bio therapies are in preclinical development. We hope to file for clinical trials authorization in several months. Follow us on LinkedIn…

What is different about Tidewave and other cell therapy for cancer?

Tidewave is targeting solid tumors with a unique broad spectrum arsenal against solid tumors that is designed to beat solid tumor defensive mechanisms and available as soon as patient are diagnosed for real time availability.

How do I get involved. How can I help Tidewave Bio’s mission?

Reach out to us at email@tidewavebio.com. We want to hear from people, patients, oncologists, surgeons and other healthcare providers, advocacy groups and investor